Home・Список акций・United Therapeutics Corp

United Therapeutics Corp

Закрыт

СекторЗдравоохранение

536.85 1.36

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

522.44

Макс.

540.58

Ключевые показатели
By Trading Economics
Доход	-89M 275M
Продажи	-8.7M 782M
P/E Средняя по отрасли	19.108 68.51
Прибыль на акцию	5.82
Рентабельность продаж	35.176
Сотрудники	1,400
EBITDA	-180M 344M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+22.93% upside

Дивиденды
By Acuity
Следующий отчет о доходах	28 окт. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	1B 26B
Предыдущая цена открытия	535.49
Предыдущая цена закрытия	536.85

Новостные настроения

By Acuity

40%

60%

120 / 340 Рейтинг в Healthcare

United Therapeutics Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 авг. 2026 г., 19:51 UTC

Social Media

News

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

6 авг. 2026 г., 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

5 авг. 2026 г., 20:02 UTC

News

Social Media

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

4 авг. 2026 г., 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

3 авг. 2026 г., 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

30 июл. 2026 г., 14:36 UTC

Event

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

29 июл. 2026 г., 20:51 UTC

Event

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

28 июл. 2026 г., 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

24 июл. 2026 г., 16:36 UTC

News

Social Media

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

22 июл. 2026 г., 19:41 UTC

News

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.

21 июл. 2026 г., 16:56 UTC

United Therapeutics Corp is seeing modest gains today, with positive sentiment from Asian markets contributing to overall investor optimism. No specific news was identified.

Сравнение c конкурентами

Изменение цены

United Therapeutics Corp Прогноз

Целевая цена

By TipRanks

22.93% рост

Прогноз на 12 месяцев

Средняя 655.13 USD 22.93%

Максимум 714 USD

Минимум 515 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для United Therapeutics Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

9 ratings

Покупка

Удержание

Продажа

Основано на мнении 9 аналитиков, присваивавших рейтинги акциям United Therapeutics Corp – Данные за последние 3 месяца.

Настроения

By Acuity

120 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.